8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
May 4, 2026·SEC
Material company update
Apr 22, 2026·SEC
Apimeds Pharmaceuticals US, Inc(APUS)Earnings, Financials & Key Ratios
APUS•NYSE
$1.47
$16M mkt cap·Price updated May 7, 2026
AboutApimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Hopewell, New Jersey. Apimeds Pharmaceuticals US, Inc. is a subsidiary of Api Meds, Inc.Show more
- Revenue$0
- EBITDA-$11.91B-936222.7%
- Net Income-$6B-431639.6%
- EPS (Diluted)-0.55+50.0%
- ROE-7.83%
- ROIC-0.01%
- Debt/Equity0.05
- Interest Coverage-42.09-289.5%
APUS Key Insights
Apimeds Pharmaceuticals US, Inc (APUS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.0x book value
✗Weaknesses
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
APUS Price & Volume
Apimeds Pharmaceuticals US, Inc (APUS) stock price & volume — 10-year historical chart
Loading chart...
APUS Growth Metrics
Apimeds Pharmaceuticals US, Inc (APUS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-431639.58%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-305.1%
Return on Capital
10 Years-293.8%
5 Years-293.8%
3 Years-125.1%
Last Year-0.02%
APUS Recent Earnings
Apimeds Pharmaceuticals US, Inc (APUS) EPS & revenue vs analyst estimates — last 4 quarters
Q2 2026Latest
May 4, 2026EPS
$0.08
Revenue
—
Q4 2025
Nov 12, 2025EPS
$0.14
Revenue
—
Q3 2025
Aug 19, 2025EPS
$0.26
Revenue
—
Q2 2025
May 19, 2025EPS
$0.05
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.08 | — |
| Q4 2025 | Nov 12, 2025 | $0.14 | — |
| Q3 2025 | Aug 19, 2025 | $0.26 | — |
| Q2 2025 | May 19, 2025 | $0.05 | — |
Based on last 12 quarters of dataView full earnings history →
APUS Peer Comparison
Apimeds Pharmaceuticals US, Inc (APUS) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HALO | 7.68B | 65.19 | 25.46 | 37.55% | 22.69% | 6.49% | ||
 ACRS | 585.63M | 4.86 | -9.17 | -58.19% | -8.3% | -62.98% | ||
 SLRX | 697.79K | 0.74 | -0.01 | -117.81% | 0.15 | |||
 NUVB | 1.67B | 4.82 | -8.03 | 6.99% | -102.06% | -44.1% | 0.03 | |
 PRGO | 1.61B | 11.72 | -1.14 | -2.75% | -43.5% | -50.65% | 1.35 | |
 PAHC | 1.75B | 43.16 | 36.27 | 27.37% | 6.29% | 30.81% | 2.67 | |
 CRL | 8.98B | 181.94 | -62.52 | -0.85% | -4.59% | -5.68% | 0.95 | |
 IQV | 30.32B | 178.64 | 22.79 | 5.87% | 8.33% | 22.11% | 2.44 |
Compare APUS vs Peers
Apimeds Pharmaceuticals US, Inc (APUS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
APUS Income Statement
Apimeds Pharmaceuticals US, Inc (APUS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 5.71K |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -5.71K▲ 0% |
| Gross Margin % | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - |
| Operating Expenses | 1.02M | 639.53K | 747.44K | 1.28M | 11.91B |
| OpEx % of Revenue | - | - | - | - | - |
| Selling, General & Admin | 529.55K | 271.53K | 648.89K | 1.28M | 10.28B |
| SG&A % of Revenue | - | - | - | - | - |
| Research & Development | 489.94K | 368K | 98.54K | 0 | 1.63B |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -1.02M▲ 0% | -639.53K▲ 37.3% | -747.44K▼ 16.9% | -1.28M▼ 70.6% | -11.91M▼ 834.2% |
| Operating Margin % | - | - | - | - | - |
| Operating Income Growth % | - | 37.27% | -16.87% | -70.6% | -834.25% |
| EBITDA | -1.02M | -639.53K | -739.63K | -1.27M | -11.91B |
| EBITDA Margin % | - | - | - | - | - |
| EBITDA Growth % | - | 37.27% | -15.65% | -72.02% | -936222.69% |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 0 |
| EBIT | -1.02M | -639.53K | -739.63K | -1.27M | -11.91M |
| Net Interest Income | -6.74K | -29.14K | -30.26K | -114.89K | -175.42K |
| Interest Income | 0 | 0 | 7.81K | 2.82K | 107.59K |
| Interest Expense | 6.74K | 29.14K | 38.07K | 117.72K | 283.01K |
| Other Income/Expense | -6.74K | -29.14K | -30.26K | -114.89K | 5.91M |
| Pretax Income | -1.03M▲ 0% | -668.67K▲ 34.8% | -777.69K▼ 16.3% | -1.39M▼ 78.7% | -6M▼ 331.7% |
| Pretax Margin % | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% |
| Net Income | -1.03M▲ 0% | -668.67K▲ 34.8% | -777.69K▼ 16.3% | -1.39M▼ 78.7% | -6B▼ 431639.6% |
| Net Margin % | - | - | - | - | - |
| Net Income Growth % | - | 34.84% | -16.31% | -78.73% | -431639.58% |
| Net Income (Continuing) | -1.03M | -668.67K | -777.69K | -1.39M | -6M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.81▲ 0% | -0.53▲ 34.8% | -0.61▼ 16.3% | -1.10▼ 79.4% | -0.55▲ 50.0% |
| EPS Growth % | - | 34.78% | -16.32% | -79.45% | 50% |
| EPS (Basic) | -0.89 | -0.58 | -0.68 | -1.20 | -0.55 |
| Diluted Shares Outstanding | 1.27M | 1.27M | 1.27M | 1.27M | 10.88M |
| Basic Shares Outstanding | 1.15M | 1.15M | 1.15M | 1.15M | 10.88M |
| Dividend Payout Ratio | - | - | - | - | - |
APUS Balance Sheet
Apimeds Pharmaceuticals US, Inc (APUS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|
| Total Current Assets | 172.17K | 6.17K | 422.08K | 13.06K | 13.98B |
| Cash & Short-Term Investments | 171.44K | 6.17K | 410.48K | 3.46K | 3.64B |
| Cash Only | 171.44K | 6.17K | 410.48K | 3.46K | 1.64B |
| Short-Term Investments | 0 | 0 | 0 | 0 | 2B |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 11.6K | 0 | 10.35B |
| Total Non-Current Assets | 0 | 0 | 0 | 0 | 150.2B |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 239.02M |
| Fixed Asset Turnover | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 149.96B |
| Total Assets | 172.17K▲ 0% | 6.17K▼ 96.4% | 422.08K▲ 6739.7% | 13.06K▼ 96.9% | 164.18B▲ 1257438331.5% |
| Asset Turnover | - | - | - | - | - |
| Asset Growth % | - | -96.42% | 6739.67% | -96.91% | 99999900% |
| Total Current Liabilities | 10.65K | 319.78K | 123.31K | 1.02M | 10.71B |
| Accounts Payable | 10.65K | 36.88K | 0 | 0 | 0 |
| Days Payables Outstanding | - | - | - | - | - |
| Short-Term Debt | 0 | 260K | 0 | 250K | 7.64B |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 180.55K | 3.06B |
| Current Ratio | 16.16x | 0.02x | 3.42x | 0.01x | 1.31x |
| Quick Ratio | 16.16x | 0.02x | 3.42x | 0.01x | 1.31x |
| Cash Conversion Cycle | - | - | - | - | - |
| Total Non-Current Liabilities | 400K | 400K | 266.89K | 346.84K | 129.45M |
| Long-Term Debt | 400K | 400K | 266.89K | 346.84K | 129.45M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 410.65K | 719.78K | 390.2K | 1.37M | 10.84B |
| Total Debt | 400K | 660K | 266.89K | 596.84K | 7.77B |
| Net Debt | 228.56K | 653.83K | -143.59K | 593.39K | 6.14B |
| Debt / Equity | - | - | 8.37x | - | 0.05x |
| Debt / EBITDA | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - |
| Interest Coverage | -151.26x | -21.95x | -19.43x | -10.81x | -42.09x |
| Total Equity | -238.48K▲ 0% | -713.61K▼ 199.2% | 31.87K▲ 104.5% | -1.36M▼ 4361.3% | 153.35B▲ 11291275.6% |
| Equity Growth % | - | -199.23% | 104.47% | -4361.31% | 11291275.6% |
| Book Value per Share | -0.19 | -0.56 | 0.03 | -1.07 | 14091.88 |
| Total Shareholders' Equity | -238.48K | -713.61K | 31.87K | -1.36M | 153.35B |
| Common Stock | 100K | 100K | 205.5K | 79.04K | 125.76M |
| Retained Earnings | -1.56M | -2.22M | -3M | -4.39M | -10.39B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
APUS Cash Flow Statement
Apimeds Pharmaceuticals US, Inc (APUS) cash flow — operating, investing & free cash flow history
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|
| Cash from Operations | -823.11K | -448.17K | -627.79K | -733.53K | -8.93M |
| Operating CF Margin % | - | - | - | - | - |
| Operating CF Growth % | - | 45.55% | -40.08% | -16.84% | -1116.83% |
| Net Income | -1.03M | -668.67K | -777.69K | -1.39M | -6M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 5.71K |
| Stock-Based Compensation | 193.54K | 193.54K | 69.99K | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 6.74K | 29.14K | 38.07K | 117.72K | -109.06K |
| Working Capital Changes | 2.84K | -2.18K | 41.84K | 538.75K | -2.82M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | 0 | 0 | 0 | 0 | -10.06M |
| Capital Expenditures | 0 | 0 | 0 | 0 | -57.33K |
| CapEx % of Revenue | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | -8M |
| Cash from Financing | 400K | 282.9K | 1.03M | 326.5K | 20.62M |
| Debt Issued (Net) | 400K | 260K | 0 | 250K | 9.3M |
| Equity Issued (Net) | 0 | 0 | 1.05M | 0 | 11.63M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 22.9K | -22.9K | 76.5K | -314.5K |
| Net Change in Cash | -423.11K▲ 0% | -165.27K▲ 60.9% | 404.31K▲ 344.6% | -407.03K▼ 200.7% | 9.63M▲ 2466.7% |
| Free Cash Flow | -823.11K▲ 0% | -448.17K▲ 45.6% | -627.79K▼ 40.1% | -733.53K▼ 16.8% | -8.98M▼ 1124.6% |
| FCF Margin % | - | - | - | - | - |
| FCF Growth % | - | 45.55% | -40.08% | -16.84% | -1124.65% |
| FCF per Share | -0.65 | -0.35 | -0.49 | -0.58 | -0.83 |
| FCF Conversion (FCF/Net Income) | 0.80x | 0.67x | 0.81x | 0.53x | 0.00x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
APUS Key Ratios
Apimeds Pharmaceuticals US, Inc (APUS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -2440.13% | - | -7.83% |
| Return on Invested Capital (ROIC) | - | - | - | - | -0.01% |
| Debt / Equity | - | - | 8.37x | - | 0.05x |
| Interest Coverage | -151.26x | -21.95x | -19.43x | -10.81x | -42.09x |
| FCF Conversion | 0.80x | 0.67x | 0.81x | 0.53x | 0.00x |
APUS SEC Filings & Documents
Apimeds Pharmaceuticals US, Inc (APUS) SEC filings — annual & quarterly reports (10-K, 10-Q)
APUS Frequently Asked Questions
Apimeds Pharmaceuticals US, Inc (APUS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Apimeds Pharmaceuticals US, Inc (APUS) grew revenue by 0.0% over the past year. Growth has been modest.
Apimeds Pharmaceuticals US, Inc (APUS) reported a net loss of $6.00B for fiscal year 2025.
Dividend & Returns
Apimeds Pharmaceuticals US, Inc (APUS) has a return on equity (ROE) of -7.8%. Negative ROE indicates the company is unprofitable.
Apimeds Pharmaceuticals US, Inc (APUS) had negative free cash flow of $9.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More APUS
Apimeds Pharmaceuticals US, Inc (APUS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates